Does the media refer more to RVTY or ADPT?

In the previous week, Adaptive Biotechnologies had 1 more articles in the media than Revvity. MarketBeat recorded 12 mentions for Adaptive Biotechnologies and 11 mentions for Revvity. Revvity's average media sentiment score of 0.55 beat Adaptive Biotechnologies' score of 0.32 indicating that Revvity is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Revvity 4 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Adaptive Biotechnologies 5 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media prefer ICLR or ADPT?

In the previous week, Adaptive Biotechnologies had 1 more articles in the media than Icon. MarketBeat recorded 12 mentions for Adaptive Biotechnologies and 11 mentions for Icon. Adaptive Biotechnologies' average media sentiment score of 0.32 beat Icon's score of 0.21 indicating that Adaptive Biotechnologies is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Icon 6 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Adaptive Biotechnologies 5 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media refer more to ADPT or TECH?

In the previous week, Adaptive Biotechnologies had 2 more articles in the media than Bio-Techne. MarketBeat recorded 12 mentions for Adaptive Biotechnologies and 10 mentions for Bio-Techne. Bio-Techne's average media sentiment score of 1.19 beat Adaptive Biotechnologies' score of 0.32 indicating that Bio-Techne is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Adaptive Biotechnologies 5 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Bio-Techne 7 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer AVTR or ADPT?

In the previous week, Adaptive Biotechnologies had 7 more articles in the media than Avantor. MarketBeat recorded 12 mentions for Adaptive Biotechnologies and 5 mentions for Avantor. Avantor's average media sentiment score of 0.80 beat Adaptive Biotechnologies' score of 0.32 indicating that Avantor is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Avantor 3 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Adaptive Biotechnologies 5 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Adaptive Biotechnologies (ADPT) Competitors

$28.61 +0.06 (+0.21%)

Closing price 09/18/2026 04:00 PM Eastern

Extended Trading

$28.59 -0.02 (-0.07%)

As of 09/18/2026 07:55 PM Eastern

Compare

ADPT vs. RVTY, CRL, ICLR, TECH, and AVTR

Should you buy Adaptive Biotechnologies stock or one of its competitors? Adaptive Biotechnologies's main competitors and comparable companies include Revvity (RVTY), Charles River Laboratories International (CRL), Icon (ICLR), Bio-Techne (TECH), and Avantor (AVTR). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "life sciences tools & services" industry.

How does Adaptive Biotechnologies compare to Revvity?

Revvity (NYSE:RVTY) and Adaptive Biotechnologies (NASDAQ:ADPT) are both healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their earnings, valuation, dividends, profitability, risk, analyst recommendations, institutional ownership and media sentiment.

In the previous week, Adaptive Biotechnologies had 1 more articles in the media than Revvity. MarketBeat recorded 12 mentions for Adaptive Biotechnologies and 11 mentions for Revvity. Revvity's average media sentiment score of 0.55 beat Adaptive Biotechnologies' score of 0.32 indicating that Revvity is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Revvity	4 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Adaptive Biotechnologies	5 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Revvity has higher revenue and earnings than Adaptive Biotechnologies. Adaptive Biotechnologies is trading at a lower price-to-earnings ratio than Revvity, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Revvity	$2.86B	5.61	$241.20M	$2.10	68.38
Adaptive Biotechnologies	$276.98M	16.49	-$59.50M	-$0.41	N/A

86.7% of Revvity shares are owned by institutional investors. Comparatively, 99.2% of Adaptive Biotechnologies shares are owned by institutional investors. 0.9% of Revvity shares are owned by company insiders. Comparatively, 5.7% of Adaptive Biotechnologies shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Revvity has a net margin of 8.16% compared to Adaptive Biotechnologies' net margin of -20.73%. Revvity's return on equity of 8.34% beat Adaptive Biotechnologies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Revvity	8.16%	8.34%	5.01%
Adaptive Biotechnologies	-20.73%	-36.81%	-13.77%

Revvity has a beta of 1.09, meaning that its stock price is 9% more volatile than the broader market. Comparatively, Adaptive Biotechnologies has a beta of 2.09, meaning that its stock price is 109% more volatile than the broader market.

Revvity currently has a consensus price target of $116.57, indicating a potential downside of 18.82%. Adaptive Biotechnologies has a consensus price target of $24.42, indicating a potential downside of 14.66%. Given Adaptive Biotechnologies' stronger consensus rating and higher probable upside, analysts clearly believe Adaptive Biotechnologies is more favorable than Revvity.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Revvity	0 Sell rating(s)	14 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.22
Adaptive Biotechnologies	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57

Summary

Revvity and Adaptive Biotechnologies tied by winning 8 of the 16 factors compared between the two stocks.

How does Adaptive Biotechnologies compare to Charles River Laboratories International?

Adaptive Biotechnologies (NASDAQ:ADPT) and Charles River Laboratories International (NYSE:CRL) are both healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their risk, earnings, analyst recommendations, dividends, profitability, media sentiment, institutional ownership and valuation.

Adaptive Biotechnologies has a beta of 2.09, suggesting that its stock price is 109% more volatile than the broader market. Comparatively, Charles River Laboratories International has a beta of 1.4, suggesting that its stock price is 40% more volatile than the broader market.

Adaptive Biotechnologies has higher earnings, but lower revenue than Charles River Laboratories International. Adaptive Biotechnologies is trading at a lower price-to-earnings ratio than Charles River Laboratories International, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Adaptive Biotechnologies	$276.98M	16.49	-$59.50M	-$0.41	N/A
Charles River Laboratories International	$4.02B	3.30	-$144.34M	-$4.85	N/A

99.2% of Adaptive Biotechnologies shares are held by institutional investors. Comparatively, 98.9% of Charles River Laboratories International shares are held by institutional investors. 5.7% of Adaptive Biotechnologies shares are held by company insiders. Comparatively, 1.3% of Charles River Laboratories International shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Charles River Laboratories International has a net margin of -5.96% compared to Adaptive Biotechnologies' net margin of -20.73%. Charles River Laboratories International's return on equity of 15.75% beat Adaptive Biotechnologies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Adaptive Biotechnologies	-20.73%	-36.81%	-13.77%
Charles River Laboratories International	-5.96%	15.75%	6.51%

In the previous week, Adaptive Biotechnologies had 7 more articles in the media than Charles River Laboratories International. MarketBeat recorded 12 mentions for Adaptive Biotechnologies and 5 mentions for Charles River Laboratories International. Charles River Laboratories International's average media sentiment score of 0.57 beat Adaptive Biotechnologies' score of 0.32 indicating that Charles River Laboratories International is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Adaptive Biotechnologies	5 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Charles River Laboratories International	1 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Adaptive Biotechnologies presently has a consensus price target of $24.42, indicating a potential downside of 14.66%. Charles River Laboratories International has a consensus price target of $273.81, indicating a potential downside of 1.40%. Given Charles River Laboratories International's stronger consensus rating and higher probable upside, analysts clearly believe Charles River Laboratories International is more favorable than Adaptive Biotechnologies.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Adaptive Biotechnologies	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57
Charles River Laboratories International	1 Sell rating(s)	3 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.67

Summary

Charles River Laboratories International beats Adaptive Biotechnologies on 9 of the 16 factors compared between the two stocks.

How does Adaptive Biotechnologies compare to Icon?

Icon (NASDAQ:ICLR) and Adaptive Biotechnologies (NASDAQ:ADPT) are both healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their risk, dividends, profitability, media sentiment, valuation, institutional ownership, analyst recommendations and earnings.

In the previous week, Adaptive Biotechnologies had 1 more articles in the media than Icon. MarketBeat recorded 12 mentions for Adaptive Biotechnologies and 11 mentions for Icon. Adaptive Biotechnologies' average media sentiment score of 0.32 beat Icon's score of 0.21 indicating that Adaptive Biotechnologies is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Icon	6 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Adaptive Biotechnologies	5 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Icon has a beta of 1.2, indicating that its stock price is 20% more volatile than the broader market. Comparatively, Adaptive Biotechnologies has a beta of 2.09, indicating that its stock price is 109% more volatile than the broader market.

Icon has a net margin of 3.99% compared to Adaptive Biotechnologies' net margin of -20.73%. Icon's return on equity of 8.02% beat Adaptive Biotechnologies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Icon	3.99%	8.02%	4.56%
Adaptive Biotechnologies	-20.73%	-36.81%	-13.77%

Icon has higher revenue and earnings than Adaptive Biotechnologies. Adaptive Biotechnologies is trading at a lower price-to-earnings ratio than Icon, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Icon	$8.25B	1.52	$229.34M	$4.26	38.52
Adaptive Biotechnologies	$276.98M	16.49	-$59.50M	-$0.41	N/A

95.6% of Icon shares are owned by institutional investors. Comparatively, 99.2% of Adaptive Biotechnologies shares are owned by institutional investors. 44.0% of Icon shares are owned by company insiders. Comparatively, 5.7% of Adaptive Biotechnologies shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Icon presently has a consensus target price of $170.07, suggesting a potential upside of 3.63%. Adaptive Biotechnologies has a consensus target price of $24.42, suggesting a potential downside of 14.66%. Given Icon's higher possible upside, research analysts plainly believe Icon is more favorable than Adaptive Biotechnologies.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Icon	2 Sell rating(s)	7 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.41
Adaptive Biotechnologies	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57

Summary

Icon beats Adaptive Biotechnologies on 11 of the 17 factors compared between the two stocks.

How does Adaptive Biotechnologies compare to Bio-Techne?

Adaptive Biotechnologies (NASDAQ:ADPT) and Bio-Techne (NASDAQ:TECH) are both healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their dividends, institutional ownership, valuation, risk, analyst recommendations, media sentiment, earnings and profitability.

Adaptive Biotechnologies has a beta of 2.09, suggesting that its share price is 109% more volatile than the broader market. Comparatively, Bio-Techne has a beta of 1.28, suggesting that its share price is 28% more volatile than the broader market.

Bio-Techne has higher revenue and earnings than Adaptive Biotechnologies. Adaptive Biotechnologies is trading at a lower price-to-earnings ratio than Bio-Techne, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Adaptive Biotechnologies	$276.98M	16.49	-$59.50M	-$0.41	N/A
Bio-Techne	$1.22B	9.34	$181.86M	$1.15	62.93

Bio-Techne has a net margin of 14.97% compared to Adaptive Biotechnologies' net margin of -20.73%. Bio-Techne's return on equity of 13.23% beat Adaptive Biotechnologies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Adaptive Biotechnologies	-20.73%	-36.81%	-13.77%
Bio-Techne	14.97%	13.23%	10.61%

99.2% of Adaptive Biotechnologies shares are held by institutional investors. Comparatively, 99.0% of Bio-Techne shares are held by institutional investors. 5.7% of Adaptive Biotechnologies shares are held by company insiders. Comparatively, 1.3% of Bio-Techne shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Adaptive Biotechnologies currently has a consensus price target of $24.42, suggesting a potential downside of 14.66%. Bio-Techne has a consensus price target of $68.92, suggesting a potential downside of 4.76%. Given Bio-Techne's higher probable upside, analysts plainly believe Bio-Techne is more favorable than Adaptive Biotechnologies.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Adaptive Biotechnologies	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57
Bio-Techne	0 Sell rating(s)	15 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.12

In the previous week, Adaptive Biotechnologies had 2 more articles in the media than Bio-Techne. MarketBeat recorded 12 mentions for Adaptive Biotechnologies and 10 mentions for Bio-Techne. Bio-Techne's average media sentiment score of 1.19 beat Adaptive Biotechnologies' score of 0.32 indicating that Bio-Techne is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Adaptive Biotechnologies	5 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Bio-Techne	7 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Bio-Techne beats Adaptive Biotechnologies on 9 of the 16 factors compared between the two stocks.

How does Adaptive Biotechnologies compare to Avantor?

Avantor (NYSE:AVTR) and Adaptive Biotechnologies (NASDAQ:ADPT) are both healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their dividends, earnings, valuation, risk, profitability, institutional ownership, analyst recommendations and media sentiment.

Avantor has a net margin of -8.81% compared to Adaptive Biotechnologies' net margin of -20.73%. Avantor's return on equity of 9.92% beat Adaptive Biotechnologies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Avantor	-8.81%	9.92%	4.75%
Adaptive Biotechnologies	-20.73%	-36.81%	-13.77%

Avantor currently has a consensus target price of $12.47, suggesting a potential downside of 19.59%. Adaptive Biotechnologies has a consensus target price of $24.42, suggesting a potential downside of 14.66%. Given Adaptive Biotechnologies' stronger consensus rating and higher probable upside, analysts clearly believe Adaptive Biotechnologies is more favorable than Avantor.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Avantor	1 Sell rating(s)	15 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.06
Adaptive Biotechnologies	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57

In the previous week, Adaptive Biotechnologies had 7 more articles in the media than Avantor. MarketBeat recorded 12 mentions for Adaptive Biotechnologies and 5 mentions for Avantor. Avantor's average media sentiment score of 0.80 beat Adaptive Biotechnologies' score of 0.32 indicating that Avantor is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Avantor	3 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Adaptive Biotechnologies	5 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Adaptive Biotechnologies has lower revenue, but higher earnings than Avantor. Adaptive Biotechnologies is trading at a lower price-to-earnings ratio than Avantor, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Avantor	$6.55B	1.60	-$530.20M	-$0.84	N/A
Adaptive Biotechnologies	$276.98M	16.49	-$59.50M	-$0.41	N/A

Avantor has a beta of 0.89, suggesting that its stock price is 11% less volatile than the broader market. Comparatively, Adaptive Biotechnologies has a beta of 2.09, suggesting that its stock price is 109% more volatile than the broader market.

95.1% of Avantor shares are owned by institutional investors. Comparatively, 99.2% of Adaptive Biotechnologies shares are owned by institutional investors. 0.3% of Avantor shares are owned by insiders. Comparatively, 5.7% of Adaptive Biotechnologies shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Summary

Adaptive Biotechnologies beats Avantor on 10 of the 16 factors compared between the two stocks.

Get Adaptive Biotechnologies News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ADPT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ADPT vs. The Competition

Export

Metric	Adaptive Biotechnologies	Life Sciences Tools & Services Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$4.56B	$10.48B	$7.26B	$13.14B
Dividend Yield	N/A	1.46%	2.57%	12.30%
P/E Ratio	-69.78	70.70	275.79	25.40
Price / Sales	16.49	108.70	695.58	114.44
Price / Cash	N/A	27.34	77.42	51.66
Price / Book	19.46	5.70	10.46	6.33
Net Income	-$59.50M	$56.67B	$3.49B	$358.33M
7 Day Performance	18.22%	4.59%	0.59%	1.12%
1 Month Performance	12.24%	1.52%	-2.01%	-2.67%
1 Year Performance	114.15%	28.13%	18.09%	6.01%

Adaptive Biotechnologies Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ADPT Adaptive Biotechnologies	1.8728 of 5 stars	$28.61 +0.2%	$24.42 -14.7%	+107.8%	$4.56B	$276.98M	N/A	624	News Coverage Insider Trade
RVTY Revvity	2.5985 of 5 stars	$128.57 +3.4%	$116.57 -9.3%	+63.6%	$14.34B	$2.91B	61.22	11,000	Insider Trade
CRL Charles River Laboratories International	1.9611 of 5 stars	$272.95 -1.9%	$265.69 -2.7%	+76.8%	$13.28B	$4.00B	N/A	19,700	Analyst Forecast
ICLR Icon	2.657 of 5 stars	$168.93 -0.2%	$170.40 +0.9%	-8.5%	$12.96B	$8.29B	39.65	40,100	News Coverage Analyst Forecast Insider Trade High Trading Volume
TECH Bio-Techne	3.3331 of 5 stars	$72.27 +0.2%	$68.92 -4.6%	+36.6%	$11.31B	$1.22B	62.84	3,000	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ADPT) was last updated on 9/19/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Adaptive Biotechnologies (ADPT) Competitors

ADPT vs. RVTY, CRL, ICLR, TECH, and AVTR

How does Adaptive Biotechnologies compare to Revvity?

Summary

How does Adaptive Biotechnologies compare to Charles River Laboratories International?

Summary

How does Adaptive Biotechnologies compare to Icon?

Summary

How does Adaptive Biotechnologies compare to Bio-Techne?

Summary

How does Adaptive Biotechnologies compare to Avantor?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ADPT vs. The Competition

Adaptive Biotechnologies Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Adaptive Biotechnologies (ADPT) Competitors

ADPT vs. RVTY, CRL, ICLR, TECH, and AVTR

How does Adaptive Biotechnologies compare to Revvity?

Does the media refer more to RVTY or ADPT?

Which has higher earnings and valuation, RVTY or ADPT?

Do institutionals & insiders have more ownership in RVTY or ADPT?

Is RVTY or ADPT more profitable?

Which has more volatility & risk, RVTY or ADPT?

Do analysts rate RVTY or ADPT?

Summary

How does Adaptive Biotechnologies compare to Charles River Laboratories International?

Which has more risk and volatility, ADPT or CRL?

Which has higher valuation and earnings, ADPT or CRL?

Do institutionals and insiders have more ownership in ADPT or CRL?

Is ADPT or CRL more profitable?

Does the media prefer ADPT or CRL?

Do analysts prefer ADPT or CRL?

Summary

How does Adaptive Biotechnologies compare to Icon?

Does the media prefer ICLR or ADPT?

Which has more volatility & risk, ICLR or ADPT?

Is ICLR or ADPT more profitable?

Which has stronger valuation and earnings, ICLR or ADPT?

Do insiders & institutionals hold more shares of ICLR or ADPT?

Do analysts recommend ICLR or ADPT?

Summary

How does Adaptive Biotechnologies compare to Bio-Techne?

Which has more risk & volatility, ADPT or TECH?

Which has higher earnings & valuation, ADPT or TECH?

Is ADPT or TECH more profitable?

Do institutionals & insiders hold more shares of ADPT or TECH?

Do analysts prefer ADPT or TECH?

Does the media refer more to ADPT or TECH?

Summary

How does Adaptive Biotechnologies compare to Avantor?

Is AVTR or ADPT more profitable?

Do analysts prefer AVTR or ADPT?

Does the media prefer AVTR or ADPT?

Which has stronger valuation & earnings, AVTR or ADPT?

Which has more volatility and risk, AVTR or ADPT?

Do insiders and institutionals hold more shares of AVTR or ADPT?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ADPT vs. The Competition

Adaptive Biotechnologies Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools